Targeted therapy with the mutant IDH2 inhibitor enasidenib for high-risk IDH2-mutant myelodysplastic syndrome

DiNardo, CD; Venugopal, S; Lachowiez, C; Takahashi, K; Loghavi, S; Montalban-Bravo, G; Wang, XM; Carraway, H; Sekeres, M; Sukkur, A; Hammond, D; Chien, KLY; Maiti, A; Masarova, L; Sasaki, K; Alvarado, Y; Kadia, T; Short, NJ; Daver, N; Borthakur, G; Ravandi, F; Kantarjian, HM; Patel, B; Dezern, A; Roboz, G; Garcia-Manero, G

DiNardo, CD (通讯作者)，UT MD Anderson Canc Ctr, Dept Leukemia, 1515 Holcombe Blvd, Houston, TX 77030 USA.

BLOOD ADVANCES, 2023; 7 (11): 2378

Abstract

The isocitrate dehydrogenase enzyme 2 (IDH2) gene is mutated in similar to 5% of patients with myelodysplastic syndrome (MDS). Enasidenib is an oral, ......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索